This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events.

Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031.

We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law.
Succession Planning

In April 2022, Paul will retire as CEO and serve as Chairman of the Board. At that time, Chris Gerard will be promoted to CEO.

Paul Kusserow, Chairman and Chief Executive Officer

Paul will transition from Chairman and CEO to Chairman on April 15th, 2021. Under Paul’s leadership Amedisys:

- Improved Home Health Quality of Patient Care Star score from 3.5 stars to 4.33 stars – leading the industry
- Migrated the entire Amedisys business to the Homecare Homebase (HCHB) platform
- Focused on employees and being the employer of choice resulting in a voluntary turnover rate of approximately 18% and landing Amedisys on Modern Healthcare’s Best Place to Work list in 2021
- Expanded Amedisys’ lines of business from Home Health and Hospice to Home Health, Hospice, Personal Care, Palliative Care, Hospital at Home and Skilled Nursing Facility (SNF) at Home
- Invested in the Hospice business growing census from approximately 4,600 to over 13,000 and increasing the number of care centers from 80 to 177
- Grew the market cap of Amedisys from $900 million to over $5.3 billion, while growing revenue by over 74%, generating substantial shareholder value

Chris Gerard, President and Chief Operating Officer

Chris, current President & COO, will transition to President and CEO and join the Board of Directors.

- Since he joined Amedisys in 2017 he has overseen the company’s home health, hospice and personal care divisions
  - 90% of the company’s employees report through Chris and nearly 100% of its revenue is generated through Chris’ segments
- Chris has a track record of more than 30 years experience in home health and hospice
- He was co-founder, President and Chief Executive Officer of IntegraCare Home Health, where he built a single home health start-up location into 54 branches, generating $71 million in annual revenues which he sold to Kindred Healthcare in 2012
- Chris was promoted Chief Operating Officer at Kindred at Home, where he was responsible for integrating a $140 million home health company and standardizing processes across a division involving 187 locations, a staff of 3,300 and revenue of $360 million and later served as President for the South Central Region of Kindred at Home with responsibility for day-to-day operations, including the integration of the Gentiva Home Health acquisition

Chris Gerard, current President & COO, will transition to President and CEO and join the Board of Directors.
Amedisys 2022 Strategy On A Page (SOAP)

Major Projects will focus on Workforce Optimization and Medicare Advantage along with core business and Contessa growth

Near-Term Headwinds Impacting the Industry and Amedisys but Long-Term Tailwinds Remain:
- The continuing pandemic has impacted our near-term growth opportunities and the way in which we do business putting a premium on clinician capacity and highlighting the need for sophisticated labor strategies
- Medicare Advantage penetration rates continue to increase – innovative models with MA plans unlock new, profitable, growth avenues
- Longer-term, demographic, psychographic, regulatory/reimbursement, and economic forces all favorable – the differentiated Amedisys service offering (Home Health, Hospice, Personal Care, Palliative Care, Hospital at Home and SNF at Home) position us accelerated growth

Continued Focus on Execution Within our Core Businesses
- Executing on our strategy provides the best opportunity for growth (Clinical Distinction, Employer of Choice, Operational Efficiency, Growth)
- At the same time, revenue growth and service offering expansion at Contessa further differentiates AMED

Our Strategic Pillars Drive Performance:
- Our major initiatives for 2022 are focused on Quality: Value-Based Purchasing (VBP) and the Hospice Care Index, Workforce Optimization: Labor Strategies and other initiatives focused on increasing clinical capacity and Growth: Organic, Inorganic and at Contessa

Core Business Near-Term Focus Areas

<table>
<thead>
<tr>
<th>Summary Focuses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home Health</td>
</tr>
<tr>
<td>Hospice</td>
</tr>
<tr>
<td>Personal Care (PCL)</td>
</tr>
<tr>
<td>Contessa (High Acuity Care)</td>
</tr>
</tbody>
</table>

Medium Term / Long Term Focus Areas

- Anticipating where the markets are going and in conjunction with our new Contessa asset, we will focus on continuing to build the expertise and capabilities needed to move into risk-taking, home-based care models:
  1. Integrating the Amedisys and Contessa offering
  2. Working with Medicare Advantage partners to test “risk” models
  3. Evaluate and expand relationships (partnerships and potential acquisitions) of additional services and capabilities needed for full risk models

Conclusion

In turbulent times, our winning strategy entails focus and execution:
- **Near term** – Be the best at core strategies, grow above market, innovate and maximize Medicare Advantage business, grow Contessa core revenue
- **Medium/Long term** – Continue to develop and build out capabilities needed for full, in-home risk-taking models
Macro Trends Impacting Healthcare Services
A number of tailwinds and headwinds will impact Amedisys in 2022 and beyond

**Payors & Model Innovation**
The shift from acute care to prevention and well-being and continued push from both CMS (VBP) and Medicare Advantage to value-based arrangements create both headwinds and tailwinds for Amedisys. Meanwhile, MA penetration continues to increase (Headwind / Tailwind)

**Demographics and Fragmentation**
A longer-term tailwind that will continue to benefit the company, the aging-population and need / demand for our services will continue to increase in coming years. Both Home Health and Hospice remain highly fragmented with consolidation in Home Health yet to occur (Tailwind)

**Reimbursement Outlook**
Positive rate updates for both Home Health and Hospice for 2022. Our payment forecasting analysis suggest we should have multiple years of continued positive rate development (Tailwind)*

**New Public Competition**
For investors looking to increase exposure to aging trends, the number of companies providing care in the home has expanded significantly. AMED has, and will continue to, meaningfully differentiate ourselves from our competition via core business performance and innovations (Neutral)

**Labor & Wage Pressures**
The fight for talent is becoming increasingly difficult as the pandemic continues to fuel demand and increased cost for key clinical positions. Workforce optimization initiatives will remain a top priority in 2022 (Headwind)

**COVID-19**
COVID-19 and its variants have impacted patients, referral sources, employees and forced healthcare services companies to re-evaluate how they do business. Excess deaths have pressured growth in both Home Health and Hospice, a headwind that will continue into 2022. Given the uncertainty of future variants, COVID-19 will likely be both a lasting headwind as we move through 2022 (Headwind)

---

*Disclaimer: Reimbursement changes subject to CMS & Administration’s agenda. Though in the short-term, rate cuts are unlikely, we are unable to predict with 100% certainty*
Demographics: Continue to be a Tailwind

The aging demographic is one of the biggest drivers to health care spending over the next several decades. The population over 75 years old is projected to grow 4% per year over the next decade while the population over 85 would grow +3% per year, then accelerate to +5%. The 85+ population is projected to more than double from 6.5m in 2018 to 14.4m in 2040 (a 122% increase).
In 2021, more than four in ten (42%) Medicare beneficiaries – 26.4 million people out of 62.7 million Medicare beneficiaries overall – are enrolled in Medicare Advantage plans. Between 2020 and 2021, total Medicare Advantage enrollment grew by about 2.4 million beneficiaries, or 10% – nearly the same growth rate as the prior year. The Congressional Budget Office (CBO) projects that the share of all Medicare beneficiaries enrolled in Medicare Advantage plans will rise to about 50 percent by 2030.

Medicare Advantage Penetration Rates & Projections

Medicare Advantage represents ~35% of AMED’s Home Health census
The continuing pandemic (nurse burnout and leaving practice) and demand for clinicians has pressured the labor markets. Clinicians are becoming harder to find and costing more to employ. Innovation in recruiting and a continued focus on retention are key initiatives to ensure we have the clinical capacity needed to care for current and future patients.

**Labor Pressures**

The U.S. needs more than 200,000 new registered nurses (RNs) each year to meet increasing health care needs and to replace nurses entering retirement. In 2019, more than half of all nurses were age 50 or older, and almost 30% were age 60 or over.

The Association of American Medical Colleges projects a national shortage of up to 122,000 physicians by 2032, including shortages of primary care physicians and specialists such as pathologists, neurologists, radiologists and psychiatrists.

The continued and accelerated aging of the U.S. population, along with the prevalence in chronic conditions and easier access to care have all increased demand for clinicals.

The recently announced vaccine mandate could further impact the pool of available clinicians. Though mandated for all above 100 employee healthcare companies, mandate will likely cause some churn in clinical staff.
The Differentiated Amedisys Platform

Hospital @ Home, SNF @ Home, Home Health, Palliative Care enable a unique patient acquisition strategy for risk-based longitudinal care programs and Hospice

**Hospital @ Home and SNF @ Home**
- Increasing patient preferences for treatment in the home
- Lower cost setting for patient encounters
- Enables and accelerates growth in risk-based Palliative and Primary Care through attribution mechanism
- Seamless transition for high-acuity services to targeted care programs

**Home-Based Palliative Care & Primary Care at Home**
- Top 10% of Medicare population drives 59% of total spend
- Enables longitudinal oversight and “pre-acute” service capability
- Increases “top of funnel” for H@H/SNF@H episodic models
- Supportive structural dynamics for addressable populations as provider risk models expand – Direct Contracting Model

**Contessa RCC**
High touch, highly coordinated patient interactions throughout 30-day or 60-day program episodes

**Amedisys Home Health**
- Many H@H and SNF@H patients require longitudinal care

**PC@H**
- Pal@Home

**Opportunity for Longitudinal Programs to Direct Patients to H@H and SNF@H**

**Home Health, Hospice**
- Home health clinical asset to be used both post-acute but also pre-acute to prevent hospitalizations
- High frequency interactions, focused on chronic condition management, relationship-based, local and longitudinal touchpoints, meeting our patients where they are and where they want to be (at home)
- Fully owned home-based care model allows for seamless identification and transition to end-of-life care when needed
## Conclusion

2022 is a setup year for 2023...

### 2022 Puts and Takes

- Positive rate updates in Home Health (+3.2%) and Hospice (+2.0%)
- Return to normalized growth in both Home Health and Hospice
  - Hospice BD staff rebuild will help to drive admissions growth in 2022
- Six-month suspension of sequestration
  - Three months at +2%, three months at +1%
- Visits per episode and clinical staffing mix (RN/LPN and PT/PTA) opportunities
- Additional investments into the business for de novo’s and projects
- Incremental EBITDA impact from Contessa
- Hospice death rate (impact unknown)
- Continued Medicare Advantage penetration increase
- Continued impact from COVID-19
  - Quarantine and testing costs
- Vaccine mandate
- Increased labor cost likely 4%-5%
  - 2%-3% historically

### Longer-Term Tailwinds

- **Significant growth in our core patient demographics** as Baby Boomers age into Home Health and Hospice
  - Over 90% of Boomers say they want to **Age in Place at home**
  - Home Health remains the most cost-effective site of care
- Industry leading quality scores position us for future benefit from **Value Based Purchasing**
- Amedisys’s **differentiated platform** sets us up for accelerated future growth and new payment / model innovations
  - Home Health
  - Hospice
  - Hospital at Home
  - SNF at Home
  - Palliative Care
  - Personal Care
- Significant revenue growth from Contessa as Hospital at Home, SNF at Home, Palliative Care and Primary Care partnerships expand
- Continued **movement towards risk-taking models** in partnership with payors
- **Industry consolidation** in both Home Health and Hospice
  - Amedisys is well positioned to capitalize with low leverage